123 Main Street, New York, NY 10001

Top Navigation with Mega Menu

Awards & Grants

Co-Dx is awarded an additional TB grant for $8.976 million by the Bill & Melinda Gates foundation to support the TB test on the new Co-Dx PCR platform, and to leverage the existing infrastructure and manufacturing capabilities of the Company’s JV in India, CoSara Diagnostics. Click here to read the press release.

Co-Dx is awarded TB and HPV grants in the amounts of $1.33 million and $987,000 by the Bill & Melinda Gates foundation to be applied towards completion of HPV test on the Co-Dx PCR platform, a disease which is estimated to cause roughly 5% of all cancers worldwide. Click here to read the press release.

Co-Dx is awarded $1.2 million in funding from the National Institutes of Health (NIH) as part of the Rapid Acceleration of Diagnostics (RADx®) Tech program for completion of its upcoming upper respiratory panel on the Company’s Co-Dx PCR testing platform. Click here to read the press release.

Co-Dx was named one of only six semifinalists in the Disruptive Technology Award competition for the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo for our Co-Dx PCR Home™ platform. The competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. Click here to read the article.

Co-Dx was recognized by BioUtah, an independent trade association serving Utah’s life sciences industry, for the Company’s high-quality, cost-efficient Logix Smart COVID-19 test deployed in Utah, across the U.S., and throughout the world. Click here to read the article.